Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Broadfin Capital Thinks ContraFect Corp (CFRX) Can Prevent 25% of Deaths

Broadfin trimmed its second-largest holding, in Flamel Technologies S.A. (ADR) (NASDAQ:FLML), by 8% during the first quarter to lower the total stake to 4.72 million shares valued at $24.87 million. The holding represents more than 12% of the company’s outstanding shares and about 7% of the fund’s portfolio value. So far this year, Flamel Technologies S.A. (ADR) (NASDAQ:FLML)’s stock has posted solid gains of 13.25%. However, this performance is overshadowed by the biotechnology industry’s rise of over 17% during the same period. The $780 million pharmaceutical company’s products include Bloxiverz and Coreg CR. The former is an injection used in the operating room to reverse the effects of non-depolarizing neuromuscular blocking agents after surgery, while the latter is used for treating high blood pressure or certain types of heart failure. After Broadfin, the two largest stockholders of Flamel Technologies S.A. (ADR) (NASDAQ:FLML) within our database are James E. Flynn‘s healthcare-focused fund Deerfield Management and Israel Englander‘s Millennium Management, with respective stakes of 4.07 million shares valued at $73.23 million and 1.83 million shares valued at $32.94 million.

During the first quarter Broadfin slightly cut its stake in Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) by 1% to 2.5 million shares valued at $65.49 million. The holding represents 8.76% of the company’s outstanding stock and 5.1% of the fund’s portfolio value. The stock of the $554.58 million biopharmaceutical company, which is engaged in developing treatments for patients with debilitating rare diseases, has fallen by 7.5% so far this year. In its financial results for the first quarter, Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) beat both the top and bottom line estimates. However, there is a considerable amount of uncertainty surrounding the company’s future prospects. It only has one main product, Juxtapid and there is a need for diversification as competition for that drug brews up. Matt Sirovich and Jeremy Mindich’s Scopia Capital is the largest stockholder of Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) within our database, owning some 5.35 million shares valued at $140.01 million.

Disclosure: None

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.